Jan D’Alvise

Ms. D’Alvise has extensive experience in the pharmaceutical, diagnostic, medical device, and drug discovery research segments of the healthcare industry. From 2016 to present, Ms. D’Alvise continues as the President and CEO of Acasti Pharma (ACST), a specialty pharma company, and serves on their board of directors.

Prior to Acasti, Ms. D’Alvise was the President and Chairman of Pediatric Bioscience, a private company that was developing a diagnostic test for autism. Before that, she was the CEO of Gish Biomedical, a cardiopulmonary medical device company, that she sold to the Sorin Group. Prior to Gish, Ms. D’Alvise was the CEO and member of the board of trustees for the Sidney Kimmel Cancer Center (SKCC), a drug discovery research institute focused on translational medicine in oncology that she sold to the Sanford Burnham Institute. Prior to SKCC, she was the Co-Founder/President & CEO/Chairman of NuGEN, Inc., and the Co-Founder, Executive VP/COO and a board member of Metrika Inc. Ms. D’Alvise built both companies from a technology concept through to successful regulatory approvals, product introduction and sustainable revenue growth. Ms. D’Alvise was also a VP of Drug Development at Syntex/Roche, and Business Unit Director of their Pain and Inflammation business, and VP of Commercial Operations at SYVA, (Syntex’s clinical diagnostics division).

Ms. D’Alvise has a B.S. in Biochemistry from Michigan Technological University and completed post-graduate studies at the University of Michigan, Stanford University, and the Wharton Business Schools. In addition to Acasti and Spectral Medical, Ms. D’Alvise serves as the Chairman of The ObG Project, Inc, a private company. She has previously served on the boards of numerous private companies and non-profits and as an entrepreneur in residence for the Stanford Graduate School of Business and the von Liebig Institute of Entrepreneurship at the University of California at San Diego.